JP2016510747A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510747A5
JP2016510747A5 JP2015561608A JP2015561608A JP2016510747A5 JP 2016510747 A5 JP2016510747 A5 JP 2016510747A5 JP 2015561608 A JP2015561608 A JP 2015561608A JP 2015561608 A JP2015561608 A JP 2015561608A JP 2016510747 A5 JP2016510747 A5 JP 2016510747A5
Authority
JP
Japan
Prior art keywords
solid oral
oral dosage
dosage form
mixture
citric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510747A (ja
JP6375314B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020763 external-priority patent/WO2014138241A1/en
Publication of JP2016510747A publication Critical patent/JP2016510747A/ja
Publication of JP2016510747A5 publication Critical patent/JP2016510747A5/ja
Application granted granted Critical
Publication of JP6375314B2 publication Critical patent/JP6375314B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561608A 2013-03-05 2014-03-05 固体経口投与剤 Active JP6375314B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361772927P 2013-03-05 2013-03-05
US61/772,927 2013-03-05
US201461925443P 2014-01-09 2014-01-09
US61/925,443 2014-01-09
PCT/US2014/020763 WO2014138241A1 (en) 2013-03-05 2014-03-05 Pharmaceuticals for oral delivery

Publications (3)

Publication Number Publication Date
JP2016510747A JP2016510747A (ja) 2016-04-11
JP2016510747A5 true JP2016510747A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-04-06
JP6375314B2 JP6375314B2 (ja) 2018-08-15

Family

ID=50391422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561608A Active JP6375314B2 (ja) 2013-03-05 2014-03-05 固体経口投与剤

Country Status (10)

Country Link
US (4) US9457086B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2964193B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6375314B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN105101950B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2014225822B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2904327C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2964193T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2774962T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL240666A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014138241A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
ES2774962T3 (es) 2013-03-05 2020-07-23 Enteris Biopharma Inc Productos farmacéuticos de administración oral
CN107427469B (zh) * 2015-01-12 2021-01-26 安特里斯生物制药公司 固体口服剂型
KR20220132598A (ko) 2020-01-28 2022-09-30 제넨테크, 인크. 암 치료를 위한 IL15/IL15R 알파 이종이량체 Fc-융합 단백질
KR20250052361A (ko) 2022-06-13 2025-04-18 비.에이.아이. 래버러터리즈, 엘엘씨 인터류킨-13 결합 시클릭 올리고펩티드 및 그의 사용 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956926A (en) * 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
NZ196348A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered antibiotics
JPS57146723A (en) * 1981-03-06 1982-09-10 Toyo Jozo Co Ltd Pharmaceutical preparation having improved absorption
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
DE69841939D1 (de) 1997-04-16 2010-11-25 Unigene Lab Inc Direkte expression von peptiden ins kulturmedium
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CA2445860A1 (en) * 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20050215476A1 (en) * 2004-01-21 2005-09-29 Unigene Laboratories Inc. Amidated parathyroid hormone fragments and uses thereof
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
WO2006026592A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
ES2437068T3 (es) 2005-06-24 2014-01-08 Enteris Biopharma, Inc. Líneas celulares para expresar enzima útil en la preparación de productos amidados
US7449896B2 (en) * 2005-07-29 2008-11-11 Ixys Corporation Current sensor using level shift circuit
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
AU2006331685A1 (en) * 2005-12-22 2007-07-05 Wyeth Methods of treating gastrointestinal tract infections with tigecycline
JPWO2007072911A1 (ja) * 2005-12-22 2009-06-04 アスビオファーマ株式会社 塩酸サプロプテリンの生体内吸収性を向上させた製剤
AR060355A1 (es) * 2007-04-04 2008-06-11 Kelly Jose Luis Aparato para disipar el agua producida por equipos de climatizacion
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
WO2009061805A1 (en) * 2007-11-05 2009-05-14 Scolr Pharma, Inc. Formulations for enhanced bioavailability of orally administered polar agents
US20100256060A1 (en) * 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
CN103764159A (zh) * 2011-06-14 2014-04-30 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
PL2720707T3 (pl) 2011-06-15 2019-06-28 Resother Pharma Aps Przeciwzapalne produkty farmaceutyczne
ES2774962T3 (es) 2013-03-05 2020-07-23 Enteris Biopharma Inc Productos farmacéuticos de administración oral
CN107427469B (zh) 2015-01-12 2021-01-26 安特里斯生物制药公司 固体口服剂型

Similar Documents

Publication Publication Date Title
JP2016510747A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015078230A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015527402A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2018506575A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2012255026A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2017105763A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2016534153A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2011201907A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2018534348A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2014129360A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015509788A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2018507914A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2018529656A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2013542247A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2016539921A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015525763A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2016503030A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2013524782A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2016511753A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2017508817A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2013542945A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2014511393A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
CL2014002896A1 (es) Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion.
JP2014521641A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)